Phase II Trial of Heated Intraperitoneal Chemotherapy and Gastrectomy for Gastric Cancer With Positive Peritoneal Cytology

  • STATUS
    Recruiting
  • End date
    Oct 1, 2027
  • participants needed
    40
  • sponsor
    National Cancer Institute (NCI)
Updated on 21 October 2022
analgesics
gastrectomy
antibiotics
cancer
endoscopy
systemic therapy
carcinoma
chemotherapy drug
gastric adenocarcinoma
neutrophil count
fluoropyrimidine
HER2
EGFR
blood transfusion
mitomycin
trastuzumab
gastric cancer
laparoscopy
cancer chemotherapy
adenocarcinoma
solid tumour
erbb2
peritoneal carcinomatosis
staging laparoscopy
pain medicine

Summary

Background

Gastric cancer is a common and serious cancer. Standard treatment is chemotherapy drugs. Researchers want to see if a new treatment helps. It is surgical removal of the cancer and heated chemotherapy delivered to the abdominal cavity called HIPEC.

Objective

To test if surgical removal of tumors plus heated intraperitoneal chemotherapy can improve survival in people with gastric cancers.

Eligibility

People ages 18 and older with gastric cancer who can have most tumors surgically removed

Design

Participants will be screened with:

  • Medical history
  • Physical exam
  • Blood, urine, and heart tests
  • Scans
  • Tissue sample from previous surgery
  • Endoscopy with biopsy: A tube with a camera goes through the mouth and into the stomach. It and takes a sample of stomach tissue. Participants might may get medicine to make them drowsy.
  • Laparoscopy: Small cuts are made in the abdomen. A thin tube with a light and camera is inserted into the abdomen. Participants sleep through the procedure.

Participants will stay in the hospital. They will have:

  • Surgery to remove as many tumors as possible.
  • HIPEC for 60 minutes: Two thin tubes are put into the abdomen. Two chemotherapy drugs are given through one tube. They are drained out through another at a temperature a few degrees above normal body temperature. Another drug is given in a vein.

Recovery for 7-21 days: Participants will have tubes in their stomach and bladder and IVs for a few days. They will get pain medicine, IV fluids, antibiotics, and blood transfusions as needed.

Participants will have visits every few months for 3 years, then one a year. Visits include physical exam, blood tests, and scans. They also include dietary assessment and questions.

Description

Background

An estimated 24,590 cases of gastric adenocarcinoma are diagnosed annually in the U.S.

The peritoneal surface is a site of metastasis found often at time of diagnosis and is a common (40%) site of recurrence.

Laparoscopy with peritoneal lavage and cytopathologic analysis is a staging modality that can identify a subset of patients with microscopic peritoneal metastasis prior to consideration for definitive surgical therapy.

Intraperitoneal chemotherapy has been employed in advanced gastric cancers and as an adjuvant with an associated improvement in survival in systematic reviews.

Objectives

Determine the overall survival in patients with cytology-positive gastric cancer treated with HIPEC and gastrectomy.

Eligibility

Histologically confirmed adenocarcinoma of the stomach.

Cytopathologic evidence of peritoneal carcinomatosis.

Medically fit for systemic chemotherapy, HIPEC and gastrectomy.

Design

Single arm, Phase II study of HIPEC and gastrectomy.

Details
Condition Gastric Adenocarcinoma, Esophagogastric Junction, Gastric Cancer
Treatment cisplatin, Surgery, Sodium Thiosulfate, Mitomycin C
Clinical Study IdentifierNCT03092518
SponsorNational Cancer Institute (NCI)
Last Modified on21 October 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Patients must have histologically or cytologically confirmed gastric adenocarcinoma or gastroesophageal junction (Siewert I-III) adenocarcinoma confirmed by the Laboratory of Pathology, NCI
Must have received systemic chemotherapy, minimum 3 months or maximum 6 months, prior to enrollment
Systemic therapy should consist of at least fluoropyrimidine-based and/or platinum based chemotherapy
Trastuzumab may be added for HER2-neu over-expressing cancers as clinically indicated
Last dose of chemotherapy within 8 weeks of enrollment with recovery to Grade 1 from chemotherapy-related toxicities
Documentation of chemotherapy administration must be obtained
Subradiographic and/or cytopathologic evidence of peritoneal carcinomatosis found at staging laparoscopy
Documentation of cytopathologic diagnosis of malignant peritoneal cytology in the absence of disseminated peritoneal disease must be obtained. If cytologic analysis reveals atypical cells of undetermined significance, a repeat lavage with cytopathologic analysis will be performed and must demonstrate evidence of malignancy
Limited peritoneal involvement found at staging laparoscopy or on final pathology that is deemed completely resectable is permitted
Age >18 years
ECOG performance status <2
Patients must have normal organ and marrow function as defined below
hemoglobin > 8.0 g/dL
absolute neutrophil count greater than or equal to 1,000/mcL
platelets greater than or equal to100,000/mcL
total bilirubin within normal institutional limits
AST(SGOT)/ALT(SGPT) less than or equal to 2.5 X institutional upper limit of
normal
creatinine < 1.5 mg/dl
eGFR (creatinine clearance) greater than or equal to 60 mL/min/1.73 m2
Physiologically able to undergo HIPEC and gastrectomy
No history of malignancy within 2 years of enrollment except for basal cell carcinoma of the skin, squamous cell skin cancer or carcinoma in situ of the cervix
Ability of subject to understand and the willingness to sign a written informed consent document
Previous exploratory laparotomy or laparoscopy with tissue biopsy or peritoneal lavage is permitted
Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately
Subjects must agree to co-enrollment on the tissue collection protocol 13C0176, Tumor, Normal Tissue and Specimens from Patients Undergoing Evaluation or Surgical Resection of Solid Tumors

Exclusion Criteria

Patients who are receiving any investigational agents
Disseminated extra-peritoneal or solid organ metastases
Includes carcinomatosis associated with clinically or radiographically evident ascites (greater than 500cc)
\--Excludes greater omentum and ovarian metastases
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
Pregnant women are excluded from this study because HIPEC and gastrectomy have not been studied in pregnant women and has the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with HIPEC and gastrectomy, breastfeeding should be discontinued if the mother is treated on this study
HIV-positive patients may be considered for this study only after consultation with a NIAID physician
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note